These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10643863)

  • 1. Regulatory science: a special update from the United States Food and Drug Administration: Preclinical issues and status of investigation of botanical drug products in the United States.
    Wu KM; DeGeorge JG; Atrakchi A; Barry E; Bigger A; Chen C; Du T; Freed L; Geyer H; Goheer A; Jacobs A; Jean D; Rhee H; Osterberg R; Schmidt W; Farrelly JG
    Toxicol Lett; 2000 Jan; 111(3):199-202. PubMed ID: 10643863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
    Lapteva L; Pariser AR
    J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
    Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
    Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
    Senderowicz AM
    Clin Cancer Res; 2010 Mar; 16(6):1719-25. PubMed ID: 20215544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A.
    Wu KM; Dou J; Ghantous H; Chen S; Bigger A; Birnkrant D
    Regul Toxicol Pharmacol; 2010 Feb; 56(1):1-3. PubMed ID: 19782117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective.
    Wu C; Lee SL; Taylor C; Li J; Chan YM; Agarwal R; Temple R; Throckmorton D; Tyner K
    J Nat Prod; 2020 Feb; 83(2):552-562. PubMed ID: 31977211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory toxicology perspectives on the development of botanical drug products in the United States.
    Wu KM; Farrelly J; Birnkrant D; Chen S; Dou J; Atrakchi A; Bigger A; Chen C; Chen Z; Freed L; Ghantous H; Goheer A; Hausner E; Osterberg R; Rhee H; Zhang K
    Am J Ther; 2004; 11(3):213-7. PubMed ID: 15133537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing Animal Models of Bacterial Pneumonia Used in Investigational New Drug Applications for the Treatment of Bacterial Pneumonia.
    Waack U; Weinstein EA; Farley JJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory issues of importance to developing anti-HIV therapeutics.
    Hastings KL
    Toxicol Pathol; 1996; 24(3):278-80. PubMed ID: 8736383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine INDs: review of clinical holds.
    Miller DL; Ross JJ
    Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example.
    Black LE; Bendele AM; Bendele RA; Zack PM; Hamilton M
    Toxicol Pathol; 1999; 27(1):22-6. PubMed ID: 10367668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative.
    Jarow JP; Casak S; Chuk M; Ehrlich LA; Khozin S
    Clin Cancer Res; 2016 May; 22(9):2111-3. PubMed ID: 26783289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggregation and analysis of secondary pharmacology data from investigational new drug submissions at the US Food and Drug Administration.
    Dodson A; Mi K; Russo DP; Scott C; Saulnier M; Snyder K; Racz R
    J Pharmacol Toxicol Methods; 2021; 111():107098. PubMed ID: 34229067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Sep; 75(188):59935-63. PubMed ID: 20879180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs.
    Black LE; Degeorge JJ; Cavagnaro JA; Jordan A; Ahn CH
    Antisense Res Dev; 1993; 3(4):399-404. PubMed ID: 8155981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; Guidance on E2F Development Safety Update Report; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Aug; 76(163):52667-8. PubMed ID: 21894658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues.
    Huang SM; Lesko LJ; Williams RL
    J Clin Pharmacol; 1999 Oct; 39(10):1006-14. PubMed ID: 10516934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.